R-IPI (Revised IPI)

The primary advantage of R-IPI is the identification of a R-CHOP-cured population (Score 0) with a 4-year OS of nearly 95%, which was not distinguishable using the original IPI.

Developed by the British Columbia Cancer Agency (BCCA) group. They demonstrated that while the same 5 risk factors were still valid in the rituximab era, the prognosis of each group had significantly improved, requiring new grouping.